Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia

British Journal of Haematology

Volumn 141, Issue 5, 2008, Pages 567-575

  Koike, Kenichi ^a   Matsuda, Kazuyuki ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Blastic crisis; Chemotherapy; Haematopoietic stem cell transplantation; Juvenile myelomonocytic leukaemia; Mutations

Indexed keywords

ANTIMETABOLITE; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MERCAPTOPURINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; ZOLEDRONIC ACID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; FATALITY; GENE; GENE INACTIVATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; KRAS2 GENE; LEUKEMIA RELAPSE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NF1 GENE; NONHUMAN; NRAS GENE; PATHOGENESIS; PRIORITY JOURNAL; PTPN11 GENE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CHILD; CHROMOSOME ABERRATIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MUTATION; PROGNOSIS;

EID: 43449083229     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07104.x     Document Type: Review

References (59)

1. Aricò, M., Biondi, A. Pui, C.H. (1997) Juvenile myelomonocytic leukemia. Blood, 90, 479 488.
2. Bader-Meunier, B., Tchernia, G., Miélot, F., Fontaine, J.L., Thomas, C., Lyonnet, S., Lavergne, J.M. Dommergues, J.P. (1997) Occurrence of myeloproliferative disorder in patients with Noonan syndrome. Journal of Pediatrics, 130, 885 889.
3. Bergstraesser, E., Hasle, H., Rogge, T., Fischer, A., Zimmermann, M., Noellke, P. Niemeyer, C.M. (2007) Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatric Blood & Cancer, 49, 629 633.
4. Bernard, F., Thomas, C., Emile, J.F., Hercus, T., Cassinat, B., Chomienne, C. Donadieu, J. (2002) Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood, 99, 2615 2616.
5. Braun, B.S., Tuveson, D.A., Kong, N., Le, D.T., Kogan, S.C., Rozmus, J., Le Beau, M.M., Jacks, T.E. Shannon, K.M. (2004) Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of The National Academy of Sciences of the USA, 101, 597 602.
6. Busque, L., Gilliland, D.G., Prchal, J.T., Sieff, C.A., Weinstein, H.J., Sokol, J.M., Belickova, M., Wayne, A.S., Zuckerman, K.S., Sokol, L. Castleberry, R.P. (1995) Clonality in juvenile chronic myelogenious leukemia. Blood, 85, 21 30.
7. Castleberry, R.P., Loh, M.L., Jayaprakash, N., Peterson, A., Casey, V., Chang, M., Widemann, B. Emanuel, P.D. (2005) Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children's Oncology Group Study. Blood (ASH Meeting Abstracts), 106, 727a.
8. Chan, R.J. Feng, G.S. (2007) PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood, 109, 862 867.
9. Chan, R.J., Leedy, M.B., Munugalavadla, V., Voorhorst, C.S., Li, Y., Yu, M. Kapur, R. (2005) Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood, 105, 3737 3742.
10. Chen, Y., Takita, J., Hiwatari, M., Igarashi, T., Hanada, R., Kikuchi, A., Hongo, T., Taki, T., Ogasawara, M., Shimada, A. Hayashi, Y. (2006) Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes, Chromosomes and Cancer, 45, 583 591.
11. Cooper, L.J., Shannon, K.M., Loken, M.R., Weaver, M., Stephens, K. Sievers, E.L. (2000) Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood, 96, 2310 2313.
12. Emanuel, P.D., Snyder, R.C., Wiley, T., Gopurala, B. Castleberry, R.P. (2000) Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood, 95, 639 645.
13. Flotho, C., Valcamonica, S., Mach-Pascual, S., Schmahl, G., Corral, L., Ritterbach, J., Hasle, H., Aricò, M., Biondi, A. Niemeyer, C.M. (1999) RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia, 13, 32 37.
14. Flotho, C., Kratz, C.P., Bergsträsser, E., Hasle, H., Stary, J., Trebo, M., van den Heuvel-Eibrink, M.M., Wójcik, D., Zecca, M., Locatelli, F. Niemeyer, C.M. on behalf of the European Working Group of Myelodysplastic Syndromes in Childhood (2007) Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood, 111, 966 967.
15. Hasle, H., Baumann, I., Bergsträsser, E., Fenu, S., Fischer, A., Kardos, G., Kerndrup, G., Locatelli, F., Rogge, T., Schultz, K.R., Stary, J., Trebo, M., van den Heuvel-Eibrink, M.M., Harbott, J., Nöllke, P. Niemeyer, C.M. (2004) European Working Group on childhood MDS. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia, 18, 2008 2014.
16. Hirano, N., Butler, M.O., Xia, Z., Berezovskaya, A., Murray, A.P., Ansén, S., Kojima, S. Nadler, L.M. (2006) Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood, 108, 2662 2668.
17. Iversen, P.O., Rodwell, R.L., Pitcher, L., Taylor, K.M. Lopez, A.F. (1996) Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R. Blood, 88, 2634 2639.
18. Iversen, P.O., Lewis, I.D., Turczynowicz, S., Hasle, H., Niemeyer, C., Schmiegelow, K., Bastiras, S., Biondi, A., Hughes, T.P. Lopez, A.F. (1997) Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood, 90, 4910 4917.
19. Iversen, P.O., Emanuel, P.D. Sioud, M. (2002) Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood, 99, 4147 4153.
20. Janik-Moszant, A., Barc-Czarnecka, M., van der Burg, M., Langerak, A.W., Hartwig, N.G., Vossen, A.C., Niemeyer, C.M., Wachowiak, J., Sonta-Jakimczyk, D. Szczepanski, T. (2008) Concomitant EBV-related B-cell proliferation and juvenile myelomonocytic leukemia in a 2-year-old child. Leukemia Research, 32, 181 184.
21. Kalra, R., Paderanga, D.C., Olson, K. Shannon, K.M. (1994) Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood, 84, 3435 3439.
22. Korthof, E.T., Snijder, P.P., de Graaff, A.A., Lankester, A.C., Bredius, R.G., Ball, L.M., Lie, J.L., Vossen, J.M. Egeler, R.M. (2005) Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. Bone Marrow Transplantation, 35, 455 461.
23. Kratz, C.P., Niemeyer, C.M., Castleberry, R.P., Cetin, M., Bergsträsser, E., Emanuel, P.D., Hasle, H., Kardos, G., Klein, C., Kojima, S., Stary, J., Trebo, M., Zecca, M., Gelb, B.D., Tartaglia, M. Loh, M.L. (2005) The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood, 106, 2183 2185.
24. Lau, R.C., Squire, J., Brisson, L., Kamel-Reid, S., Grunberger, T., Dubé, I., Letarte, M., Shannon, K. Freedman, M.H. (1994) Lymphoid blast crisis of B-lineage phenotype with monosomy 7 in a patient with juvenile chronic myelogenous leukemia (JCML). Leukemia, 8, 903 908.
25. Le, D.T., Kong, N., Zhu, Y., Lauchle, J.O., Aiyigari, A., Braun, B.S., Wang, E., Kogan, S.C., Le Beau, M.M., Parada, L. Shannon, K.M. (2004) Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood, 103, 4243 4250.
26. Locatelli, F., Nollke, P., Zecca, M., Korthof, E., Lanino, E., Peters, C., Pession, A., Kabisch, H., Uderzo, C., Bonfim, C.S., Bader, P., Dilloo, D., Stary, J., Fischer, A., Revesz, T., Fuhrer, M., Hasle, H., Trebo, M., van den Heuvel-Eibrink, M.M., Fenu, S., Strahm, B., Giorgiani, G., Bonora, M.R., Duffner, U. Niemeyer, C.M. European Working Group on Childhood MDS; European Blood and Marrow Transplantation Group (2005) Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood, 105, 410 419.
27. Lorenzana, A., Lyons, H., Sawaf, H., Higgins, M., Carrigan, D. Emanuel, P.D. (2002) Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant. Journal of Pediatric Hematology and Oncology, 24, 136 141.
28. Luna-Fineman, S., Shannon, K.M., Atwater, S.K., Davis, J., Masterson, M., Ortega, J., Sanders, J., Steinherz, P., Weinberg, V. Lange, B.J. (1999) Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood, 93, 459 466.
29. Mahgoub, N., Taylor, B.R., Gratiot, M., Kohl, N.E., Gibbs, J.B., Jacks, T. Shannon, K.M. (1999) In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood, 94, 2469 2476.
30. Manabe, A., Okamura, J., Yumura-Yagi, K., Akiyama, Y., Sako, M., Uchiyama, H., Kojima, S., Koike, K., Saito, T. Nakahata, T. MDS Committee of the Japanese Society of Pediatric Hematology (2002) Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia, 16, 645 649.
31. Matsuda, K., Matsuzaki, S., Miki, J., Hidaka, E., Yanagisawa, R., Nakazawa, Y., Sakashit, K., Kamijo, T., Asami, K., Sano, K. Koike, K. (2006) Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile myelomonocytic leukemia: the growth of a 6-MP-refractory clone that already exists at onset. Leukemia, 20, 485 490.
32. Matsuda, K., Nakazawa, Y., Sakashita, K., Shiohara, M., Yamauchi, K. Koike, K. (2007a) Acquirement of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation. Haematologica, 92, 1576 1578.
33. Matsuda, K., Shimada, A., Yoshida, N., Ogawa, A., Watanabe, A., Yajima, S., Iizuka, S., Koike, K., Yanai, F., Kawasaki, K., Yanagimachi, M., Kikuchi, A., Ohtsuka, Y., Hidaka, E., Yamauchi, K., Tanaka, M., Yanagisawa, R., Nakazawa, Y., Shiohara, M., Manabe, A., Kojima, S. Koike, K. (2007b) Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood, 109, 5477 5480.
34. Matsuzaki, S., Matsuda, K., Miki, J., Nakazawa, Y., Sakashita, K., Kamijo, T., Hidaka, E. Koike, K. (2005) Development of two cytogenetically abnormal clones from multipotential hematopoietic stem cells in a patient with juvenile myelomonocytic leukemia. Leukemia Research, 29, 1069 1072.
35. Messiaen, L.M., Callens, T., Mortier, G., Beysen, D., Vandenbroucke, I., Van Roy, N., Speleman, F. Paepe, A.D. (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutation, 15, 541 555.
36. Metzner, A., Horstmann, M.A., Fehse, B., Ortmeyer, G., Niemeyer, C.M., Stocking, C., Mayr, G.W. Jucker, M. (2007) Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations. Gene Therapy, 14, 699 703.
37. Mohi, M.G., Williams, I.R., Dearolf, C.R., Chan, G., Kutok, J.L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., Akashi, K., Gilliland, D.G. Neel, B.G. (2005) Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell, 7, 179 191.
38. Morerio, C., Acquila, M., Rosanda, C., Rapella, A., Dufour, C., Locatelli, F., Maserati, E., Pasquali, F. Panarello, C. (2004) HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Research, 64, 2649 2651.
39. Niemeyer, C.M. Locatelli, F. (2006) Chronic myeloproliferative disorders. In : Childhood Leukemia (ed. by C.H. Pui pp. 571 598. Cambridge University Press, New York.
40. Niemeyer, C.M., Aricò, M., Basso, G., Biondi, A., Cantu Rajnoldi, A., Creutzig, U., Haas, O., Harbott, J., Hasle, H., Kerndrup, G., Locatelli, F., Mann, G., Stollmann-Gibbels, B., van't Veer-Korthof, E.T., van Wering, E. Zimmermann, M. (1997) Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on myelodysplastic syndromes in childhood (EWOG-MDS). Blood, 89, 3534 3543.
41. Niemeyer, C.M., Fenu, S., Hasle, H., Mann, G., Stary, J. van Wering, E. (1998) Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood, 91, 365 367.
42. Ohtsuka, Y., Manabe, A., Kawasaki, H., Hasegawa, D., Zaike, Y., Watanabe, S., Tanizawa, T., Nakahata, T. Tsuji, K. (2005) RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro. Blood, 106, 3134 3141.
43. Osaka, M., Matsuo, S., Koh, T. Sugiyama, T. (1997) Loss of heterozygosity at the N-ras locus in 7,12-dimethylbenz[a] anthracene-induced rat leukemia. Molecular Carcinogenesis, 18, 206 212.
44. Schubbert, S., Lieuw, K., Rowe, S.L., Lee, C.M., Li, X., Loh, M.L., Clapp, D.W. Shannon, K.M. (2005) Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood, 106, 311 317.
45. Scrideli, C.A., Baruffi, M.R., Rogatto, S.R., Valera, E.T., Defavery, R. Tone, L.G. (2003) B lineage acute lymphoblastic leukemia transformation in a child with juvenile myelomonocytic leukemia, type 1 neurofibromatosis and monosomy of chromosome 7. Possible implications in the leukemogenesis. Leukemia Research, 27, 371 374.
46. Sheng, X.M., Kawamura, M., Ohnishi, H., Ida, K., Hanada, R., Kojima, S., Kobayashi, M., Bessho, F., Yanagisawa, M. Hayashi, Y. (1997) Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. Leukemia Research, 21, 697 701.
47. Shimada, H., Shima, H., Shimasaki, N., Yoshihara, H., Mori, T. Takahashi, T. (2005) Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation. Annals of Oncology, 16, 1400.
48. Side, L., Taylor, B., Cayouette, M., Conner, E., Thompson, P., Luce, M. Shannon, K.M. (1997) Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. New England Journal of Medicine, 336, 1713 1720.
49. Side, L.E., Emanuel, P.D., Taylor, B., Franklin, J., Thompson, P., Castleberry, R.P. Shannon, K.M. (1998) Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood, 92, 267 272.
50. Smith, F.O., King, R., Nelson, G., Wagner, J.E., Robertson, K.A., Sanders, J.E., Bunin, N., Emaunel, P.D. Davies, S.M. (2002) National Marrow Donor Program. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. British Journal of Haematology, 116, 716 724.
51. Stiller, C.A., Chessells, J.M. Fitchett, M. (1994) Neurofibromatosis and childhood leukemia/lymphoma: a population-based UKCCSG study. British Journal of Cancer, 70, 969 972.
52. Tartaglia, M., Mehler, E.L., Goldberg, R., Zampino, G., Brunner, H.G., Kremer, H., van der Burgt, I., Crosby, A.H., Ion, A., Jeffery, S., Kalidas, K., Patton, M.A., Kucherlapati, R.S. Gelb, B.D. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature Genetics, 29, 465 468.
53. Tartaglia, M., Niemeyer, C.M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J.D. Gelb, B.D. (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 34, 148 150.
54. Tono, C., Xu, G., Toki, T., Takahashi, Y., Sasaki, S., Terui, K. Ito, E. JAK2 (2005) Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. Leukemia, 19, 1843 1844.
55. Woods, W.G., Barnard, D.R., Alonzo, T.A., Buckley, J.D., Kobrinsky, N., Arthur, D.C., Sanders, J., Neudorf, S., Gold, S. Lange, B.J. (2002) Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. Journal of Clinical Oncology, 20, 434 440.
56. Worth, A., Rao, K., Webb, D., Chessells, J., Passmore, J. Veys, P. (2003) Successful treatment of juvenile myelomonocytic leukemia relapsing post stem cell transplant using donor lymphocyte infusion. Blood, 101, 1713 1714.
57. Yoshimi, A., Niemeyer, C.M., Bohmer, V., Duffner, U., Strahm, B., Kreyenberg, H., Dilloo, D., Zintl, F., Claviez, A., Wossmann, W., Kremens, B., Holter, W., Niethammer, D., Beck, J.F., Kontny, U., Nollke, P., Klingebiel, T. Bader, P. (2005a) Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. British Journal of Haematology, 129, 542 549.
58. Yoshimi, A., Bader, P., Matthes-Martin, S., Stary, J., Sedlacek, P., Duffner, U., Klingebiel, T., Dilloo, D., Holter, W., Zintl, F., Kremens, B., Sykora, K.W., Urban, C., Hasle, H., Korthof, E., Revesz, T., Fischer, A., Nollke, P., Locatelli, F. Niemeyer, C.M. (2005b) European Working Group of MDS in childhood (EWOG-MDS). Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia, 19, 971 977.
59. Yoshimi, A., Mohamed, M., Bierings, M., Urban, C., Korthof, E., Zecca, M., Sykora, K.W., Duffner, U., Trebo, M., Matthes-Martin, S., Sedlacek, P., Klingebiel, T., Lang, P., Fuhrer, M., Claviez, A., Wossmann, W., Pession, A., Arvidson, J., O'Marcaigh, A.S., van den Heuvel-Eibrink, M.M., Stary, J., Hasle, H., Nollke, P., Locatelli, F. Niemeyer, C.M. (2007) Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia, 21, 556 560.